(“Diaceutics” or “the Company”)
New Vice President of Finance appointment
Diaceutics PLC, (AIM: DXRX), announces the appointment of Nikita Lynn as Vice President of Finance. Nikita has been promoted to this role following her tenure as Senior Director of Corporate Advancement.
In her new role within Diaceutics, Nikita will be responsible for the financial operations and corporate development of the Company, reporting to the CFO, Board of Directors and Non-Executive Directors. She brings extensive experience in financial reporting, taxation and auditing for public companies to the position.
Before joining Diaceutics in August 2020, Nikita was a Senior Manager at PwC where she spent approximately six years in the Assurance Department, working predominantly within the audit team. During this time, she also worked on reporting accountant engagements, which included project leading the IPOs of Fusion Antibodies in December 2017 and Diaceutics PLC in March 2019.
Nikita trained and qualified as a Chartered Accountant with the Institute of Chartered Accountants, Ireland, and is an active contributor with the Institute of Chartered Accountants Ireland, Ulster Society, having gained experience across several committee roles.
Commenting on the appointment, Philip White , Chief Financial Officer of Diaceutics, said: “An expert in finance, Nikita has a stellar track record and in-depth experience within the technology, pharma, and manufacturing sectors. During her time as Senior Director of Corporate Advancement at Diaceutics, she has demonstrated the leadership abilities which will be invaluable in helping us advance our mission and solutions enabled by DXRX – The Diagnostic Network®, and in unlocking the transformative financial value of platform business models.”
Nikita Lynn, Vice President of Finance, Diaceutics added: “I’m thrilled to commence a new chapter in my Diaceutics career, and to continue working alongside a diverse group of talented professionals aligned on a common goal – to provide every patient with the treatment they deserve. I look forward to continuing to work with the Diaceutics finance and executive management team as we continue to drive the growth of Diaceutics PLC and DXRX.”
Enquiries:
Diaceutics PLC | |||
Philip White, Chief Financial Officer | Via Walbrook PR | ||
Cenkos Securities plc (Nomad & Broker) | Tel: +44(0)20 7397 8900 | ||
Callum Davidson / Giles Balleny | |||
Michael Johnson (Sales) | |||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | ||
Anna Dunphy | Tel: +44 (0)7876 741 001 | ||
Paul McManus | Tel: +44 (0)7980 541 893 | ||
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX – our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world’s largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. www.diaceutics.com
About DXRX – The Diagnostic Network®
DXRX is the world’s first diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.